US009408887B2

(12) **United States Patent**
Kleinberg et al.

(10) **Patent No.: US 9,408,887 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **INTERMITTENT DOSING REGIMEN FOR TREATING BREAST CANCER**

(71) Applicants: **David L. Kleinberg**, New York, NY (US); **Mary Helen Barcellos-Hoff**, New York, NY (US)

(72) Inventors: **David L. Kleinberg**, New York, NY (US); **Mary Helen Barcellos-Hoff**, New York, NY (US)

(73) Assignee: **New York University**, New York, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/487,197**

(22) Filed: **Sep. 16, 2014**

(65) **Prior Publication Data**

US 2015/0099700 A1 Apr. 9, 2015

Related U.S. Application Data

(62) Division of application No. 13/564,873, filed on Aug. 2, 2012, now Pat. No. 8,835,123.

(60) Provisional application No. 61/574,414, filed on Aug. 2, 2011.

(51) **Int. Cl.**

A61K 38/12	(2006.01)
A61K 38/31	(2006.01)
G01N 33/574	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 38/12*** (2013.01); ***A61K 38/31*** (2013.01); ***G01N 33/57415*** (2013.01); *G01N 2800/50* (2013.01); *G01N 2800/52* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,946,256	B1	9/2005	McKeon et al.	435/7.1
7,473,761	B2	1/2009	Albert et al.	
2009/0325863	A1	12/2009	Kleinberg et al.	

OTHER PUBLICATIONS

DiLeo et al. (Breast Cancer Res Treat. Jun. 1995;34(3):237-244).*

Kahan et al., Int J Cancer. Aug. 12, 1999;82(4):592-598.*

Ruan, W et al (2006) Mol Endocrinology 20(2):426-436.*

Wright et al., "BRCA1 breast tumors contain distinct CD44+/CD24– and CD133+ cells with cancer stem cell characteristics", Breast Cancer Research, 2008, 10, 1-16.

Burga et al., "Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers", Cancer Research, 2009, 69, 1273-1278.

Lim et al., "Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers", Nature Medicine, 2009, 15, 907-913.

Molyneux et al., "BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells", Cell Stem Cell, 2010, 7, 403-417.

Lamberts et al., "The role of somatostatin and its analogs in the diagnosis and treatment of tumors", Endocrin Rev, 1991, 12, 450-481.

Patel et al., "The somatostatin receptor family", Life Sciences, 1995, 57, 1249-1265.

Patel et al., "Molecular biology of somatostatin receptor subtypes", Metabolism, 1996, 45, 31-38.

Reisine et al., "Molecular biology of somatostatin receptors", Endocrin Rev, 1995, 16, 427-442.

Buscail et al., "Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms", Proc Natl Acad Sci, 1995, 92, 1580-1584.

Bell et al., "Molecular biology of somatostatin receptors", Trends Neuroscience, 1993, 16, 34-38.

Ruan et al., "SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: Mediated through somatostatin subtype receptor 3?", Molecular Endocrinology, 2006, 20, 426-436.

London et al., "A prospective study of benign breast disease and the risk of breast cancer", JAMA, 1992, 267, 941-944.

Palli et al., "Benign breast disease and breast cancer: A case-control study in a cohort in Italy", Int J Cancer, 1991, 47, 703-706.

Dupont et al., "Risk factors for breast cancer in women with proliferative breast disease", N Engl J Med, 1985, 312, 146-151.

Dupont et al., "Breast cancer risk associated with proliferative breast disease and atypical hyperplasia", Cancer, 1993, 71, 1258-1265.

Hartmann et al., "Benign breast disease and the risk of breast cancer", N Engl J Med, 2005, 353, 229-237.

Morrison et al., "Asymmetric and symmetric stem-cell divisions in development and cancer", Nature, 2006, 441, 1068-1074.

Fleseriu et al., "Medical management of Cushing's Disease: What is the future?", Pituitary, 2012, 15, 330-341.

Colao et al., "A 12-month phase 3 study of pasireotide in Cushing's Disease", N Eng J Med, 2012, 366, 914-924.

Ruan et al., "Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action", Endocrinology, 2005, 146, 1170-1178.

Boccardo et al., "Management of breast cancer: Is there a role for somatostatin and its analogs?", Chemotherapy, 2001, 47, 62-77.

Fedele et al., SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas, Clin Cancer Res, 2007, 13, 2738-2744.

(Continued)

Primary Examiner — Daniel C Gamett

(74) *Attorney, Agent, or Firm* — Klauber & Jackson LLC

(57) **ABSTRACT**

Diagnostic and therapeutic methods pertaining to diseases and disorders of the breast, uterus and ovary are encompassed herein. More particularly, diagnostic methods for early detection of progenitor cells of breast, uterine, and ovarian cancers are described herein. The identification of markers for these cancer predisposing progenitor cells, which co-express the progesterone receptor (PR) and p63, provides tools and methods of use thereof that facilitate early detection of increased frequency of PR/p63 double positive (PR/p63+) progenitor cells in asymptomatic patients and thus, early detection of increased cancer risk in such patients and assessment, diagnostic stratification, and evaluation of therapeutic intervention in symptomatic patients. Therapeutic methods are also encompassed herein, which include detection of PR/p63+ progenitor cells in a patient, wherein detection of increased frequency of PR/p63+ progenitor cells provides information on which basis a determination of therapeutic regimen or an assessment of an ongoing therapeutic regimen can be made.

9 Claims, 5 Drawing Sheets